RxDoctor Payments DataLook up a doctor →

Gary Spector, MD

Internal Medicine · Milford, CTNPI 1093816175

Payments from drug & device makers

$32,400in general payments, 2019–2025

Across 882 payments — averaging $36.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$11K
  • AstraZeneca$6K
  • AbbVie$3K
  • Boehringer Ingelheim$3K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$9,80030%
  • Food & beverage$22,57670%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK62$11,266
AstraZeneca141$5,819
AbbVie(2 entities)178$2,843
Boehringer Ingelheim43$2,506
Lilly USA, LLC42$1,335
Novo Nordisk50$1,204
E.r. Squibb & Sons, L.L.C.99$920
Merck24$526
Pfizer29$508
Amgen(2 entities)11$434
Inspire Medical Systems, Inc.13$390
Takeda Pharmaceuticals U.S.A., Inc.14$307
Amarin Pharma, Inc.25$292
Abbott6$277
Exact Sciences12$273
Corcept Therapeutics6$265
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$257
Bayer7$254
Lumenis BE Inc1$182
Mylan Specialty L.p.8$164
ARS Pharmaceuticals Operations, Inc.3$162
Ironwood Pharmaceuticals, Inc7$154
Johnson & Johnson3$154
Eisai Inc.8$149
Bard Peripheral Vascular, Inc.1$140
Biohaven Pharmaceutical Holding Company Ltd.4$134
Genentech USA, Inc.6$103
Astellas Pharma US Inc1$100
Sanofi-aventis U.S. LLC5$94
Almatica Pharma LLC5$80
Philips North America LLC1$75
Inari Medical, Inc.1$68
Cequr Corporation2$67
Axsome Therapeutics, Inc.3$64
Currax Pharmaceuticals LLC4$63
Endo Pharmaceuticals Inc.3$60
Novartis3$52
Mannkind Corporation1$50
Optinose US, Inc.2$43
Lucid Diagnostics Inc.2$43
Amneal Pharmaceuticals LLC2$40
Viatris Specialty LLC2$37
Biohaven Pharmaceuticals, Inc.1$32
Linus Health, Inc.1$29
Esperion Therapeutics, Inc.1$29
Aytu Biopharma, Inc.1$27
Phathom Pharmaceuticals, Inc.1$26
Alkermes, Inc.1$26
Baxter Healthcare1$22
Otsuka America Pharmaceutical, Inc.1$21
Intra-sana Laboratories1$21
Sumitomo Pharma America, Inc.1$21
Xeris Pharmaceuticals, Inc.1$20
Boston Scientific1$20
Heartflow, Inc.1$19
Clarus Therapeutics Inc.1$19
Paratek Pharmaceuticals, Inc.1$17
Circassia Inc.1$16
Vistapharm, Inc.1$16
Dexcom, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,400 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$121,165
Medicare patients
269
Services billed
1,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$128,354
JardianceEmpagliflozin101$118,251
FarxigaDapagliflozin Propanediol77$81,544
Synjardy XrEmpagliflozin/Metformin Hcl46$45,045
XareltoRivaroxaban29$35,385
Xigduo XrDapaglifloz Propaned/Metformin17$31,135
JanuviaSitagliptin Phosphate20$19,895
RybelsusSemaglutide13$17,320
MounjaroTirzepatide15$15,597
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,923
TrulicityDulaglutide12$11,538
Tresiba Flextouch U-200Insulin Degludec16$10,969
EliquisApixaban15$9,794
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,980
TradjentaLinagliptin15$7,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$2,506$170,687162 claims
Novo NordiskOzempic, Rybelsus$1,204$145,67394 claims
AstraZenecaFarxiga$5,819$81,54477 claims
Johnson & JohnsonXarelto$154$35,38529 claims
Lilly USA, LLCMounjaro, Trulicity$1,335$27,13527 claims
MerckJanuvia$526$19,89520 claims
GSKTrelegy Ellipta$11,266$12,92320 claims
PfizerEliquis, Paxlovid$508$11,22334 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$40$2,935307 claims
AbbVieSynthroid$2,843$87225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Milford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →